World's Best Scientists 2026 revealed!
Umberto Vitolo

Umberto Vitolo

D-Index & Metrics

Medicine

D-Index
85
Citations
26562
World Ranking
14610
National Ranking
564

Umberto Vitolo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Umberto Vitolo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 569 publications — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Umberto Vitolo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Umberto Vitolo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Umberto Vitolo is affiliated with the University of Turin in Italy. Their research primarily falls within the field of Medicine, with a focus on subfields including Pathology and Forensic Medicine, Oncology, Genetics, Radiology, Nuclear Medicine and Imaging, and Neurology.

Their scholarly output includes significant work related to lymphoma and leukemia, reflected in numerous publications and frequent appearances in specific journals and conferences. The major topics addressed in their research include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • CNS Lymphoma Diagnosis and Treatment
  • Monoclonal and Polyclonal Antibodies Research
  • Viral-associated cancers and disorders
  • Cutaneous lymphoproliferative disorders research

Vitolo has had multiple frequent coauthors, indicating collaborative research engagements. Among these are:

  • Marek Trněný
  • Annalisa Chiappella
  • Raúl Córdoba
  • Alessandra Tucci
  • Andrea Evangelista

Their publications have appeared most often in the following venues:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Hematological Oncology
  • HemaSphere
  • Blood Advances

Among recent papers involving or relevant to their research area are:

  • "ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma," 2021, Journal of Clinical Oncology
  • "Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials," 2022, Blood
  • "Treatment strategies for patients with diffuse large B-cell lymphoma," 2022, Cancer Treatment Reviews
  • "A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA," 2020, Journal of Hematology & Oncology
  • "Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project," 2021, Blood

Best Publications

  • Follicular lymphoma international prognostic index.

    Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White

  • Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

    Andrea Gallamini;Martin Hutchings;Luigi Rigacci;Lena Specht

  • Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

    Massimo Federico;Monica Bellei;Luigi Marcheselli;Stefano Luminari

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    H Tilly;M Gomes da Silva;U Vitolo;A Jack

  • Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

    Andrea Gallamini;Caterina Stelitano;Roberta Calvi;Monica Bellei

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Dreyling;M Ghielmini;S Rule;G Salles

  • Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

    E. Zucca;A. Conconi;T.I. Mughal;A.H. Sarris

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

    Simonetta Viviani;Pier Luigi Zinzani;Alessandro Rambaldi;Ercole Brusamolino

  • Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

    Umberto Vitolo;Marek Trněný;David Belada;John M Burke

  • The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease

    Andrea Gallamini;Luigi Rigacci;Francesco Merli;Luca Nassi

  • Hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma

    Manel Esteller;Manel Esteller;Gianluca Gaidano;Steven N. Goodman;Vittorina Zagonel

  • Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

    Marco Ladetto;Federica De Marco;Fabio Benedetti;Umberto Vitolo

  • Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

    Patrizia Pregno;Annalisa Chiappella;Marilena Bellò;Barbara Botto

  • Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

    Emanuele Zucca;Annarita Conconi;Daniele Laszlo;Armando López-Guillermo

  • Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

    M Dreyling;F Morschhauser;K Bouabdallah;D Bron

  • First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial

    Umberto Vitolo;Annalisa Chiappella;Andrés J.M. Ferreri;Maurizio Martelli

  • Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia

    Daniela Capello;Umberto Vitolo;Laura Pasqualucci;Silvia Quattrone

  • R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi

    Massimo Federico;Stefano Luminari;Alessandra Dondi;Alessandra Tucci

Frequent Co-Authors

Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Gianluca Gaidano
Gianluca Gaidano University of Eastern Piedmont Amadeo Avogadro
Paolo Corradini
Paolo Corradini University of Milan
Massimo Federico
Massimo Federico University of Modena and Reggio Emilia
Stefano Pileri
Stefano Pileri European Institute of Oncology
Mario Boccadoro
Mario Boccadoro University of Turin
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Francesco Di Raimondo
Francesco Di Raimondo University of Catania
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Giovanni Martinelli
Giovanni Martinelli University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in expanding your healthcare career opportunities beyond studying Medicine in the USA? Numerous online degree options allow you to gain valuable credentials flexibly and affordably.

If you’re looking for a foundational program, consider the cheapest online health science degree options. These programs can give you a broad understanding of health systems and serve as a stepping stone to more advanced roles.

For those aiming for healthcare leadership, pursuing one of the most affordable mha programs can prepare you to manage hospitals, clinics, and other healthcare institutions.

Advanced practitioners might consider the best online dnp programs, which focus on clinical practice at the highest level for nurses. Pharmacists seeking a doctoral-level credential at their own pace can explore a 3 year online pharmd program—an efficient pathway into advanced pharmacy roles.

Each of these online degrees provides flexibility and opens distinct career pathways in the rapidly evolving healthcare sector.

Best Scientists Citing Umberto Vitolo

Trending Scientists

Recently Published Articles